Back to results
US 2017/0291956 A1Published application
HER3 Inhibition in Low-grade Serous Ovarian Cancers
OwnerDavid Livingston, Joyce Liu +1inventors
InventorsDavid Livingston, Joyce Liu, Ronny Drapkin
Life of this patent
Estimating the term…
Abstract
Methods of treatment of cancer are provided. In particular, methods of treatment of low-grade serous ovarian cancers by inhibiting signaling of an EGFR family member are provided.
Claims39
A method of treating cancer in a subject, the method comprising:
- administering to the subject a therapeutically effective amount of an antibody or fragment thereof that specifically binds to an Epidermal Growth Factor Receptor (EGFR) family member;
- wherein the cancer is low-grade serous ovarian cancer.
A method of treating cancer in a subject, the method comprising:
- administering to the subject a therapeutically effective amount of an agent that inhibits signaling of an EGFR family member in the cancer, wherein the cancer is low-grade serous ovarian cancer.
A method of treating low-grade serous ovarian cancer comprising:
- selecting a patient suffering from low-grade serous ovarian cancer;
- and
- administering an antibody or fragment thereof that specifically binds to a HER3 receptor, such that the antibody or fragment thereof binds to a conformational epitope comprising amino acid residues within domain 2 and domain 4 of the HER3 receptor and blocks both ligand-dependent and ligand-independent signal transduction, thereby treating low-grade serous ovarian cancer.
(canceled)
Dependencies are inferred from the claim text.